In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...
VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis. With an initial $4 million in funding, the ...
Longtime runner Annie Saunders didn’t let a 2021 diagnosis of multiple sclerosis sideline her passions. If anything, the 40-year-old Irwin native pushes harder — through weakness and imbalance caused ...
Share on Pinterest Stem cell therapy could help halt the progression of cognitive impairment in multiple sclerosis. Image credit: TEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images. About 2.8 million people ...
Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...
In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...
Bionxt has completed manufacturing of a batch of BNT23001, its under-the-tongue formulation of cladribine, for use in MS ...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results